Barinthus Biotherapeutics plc (BRNS)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
As of September 9, 2026, Barinthus Biotherapeutics plc was acquired by Clywedog Therapeutics, Inc., in a reverse merger transaction. Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
Barinthus Biotherapeutics plc has not issued a press release in this window.
SEC filings
All filings →Barinthus Biotherapeutics plc has not filed an SEC document in this window.
Insider trades
All insider trades →Barinthus Biotherapeutics plc has no reported insider trades in the last 90 days.